ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models

Nuclear Medicine and Biology

Volumn 40, Issue 1, 2013, Pages 15-22

  Ogasawara, Annie ^a   Tinianow, Jeff N ^a   Vanderbilt, Alexander N ^a   Gill, Herman S ^a   Yee, Sharon ^a   Flores, Judith E ^a   Williams, Simon Peter ^a   Ashkenazi, Avi ^a   Marik, Jan ^a  

^a GENENTECH INC   (United States)

Author keywords

89Zr; Apoptosis; Cancer therapy; Monoclonal antibodies; PET

Indexed keywords

ANTINEOPLASTIC AGENT; BAVITUXIMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PGN 635; NUCLEOTIDE; PACLITAXEL; PHOSPHATIDYLSERINE; PRO 598; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIGEN BINDING; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNODETECTION; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUCLEIC ACID PROBE; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; TUMOR MODEL; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; PHOSPHATIDYLSERINES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; ZIRCONIUM;

EID: 84871918783     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.09.001     Document Type: Article

References (41)

1. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000, 1:120-129.
2. Mattson M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxidants & redox signaling 2006, 8:1997-2006.
3. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
5. Brenner D., Mak T.W. Mitochondrial cell death effectors. Current opinion in cell biology 2009, 21:871-877.
6. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science (New York, N.Y.) 1998, 281:1305-1308.
7. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nature Immunology 2009, 10:348-355.
8. Biton S., Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 2011, 145:92-103.
9. Yang A., Wilson N.S., Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Current opinion in Cell Biology 2010, 22:837-844.
10. Tait J.F. Imaging of apoptosis. J Nucl Med 2008, 49:1573-1576.
11. Blankenberg F.G. In vivo imaging of apoptosis. Cancer biology & therapy 2008, 7:1525-1532.
12. Blankenberg F.G. In vivo detection of apoptosis. J Nucl Med 2008, 49(Suppl. 2):81S-95S.
13. Zhou L., Wang W., Dicker D.T., Humphreys R.C., El-Deiry W.S. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer biology & therapy 2011, 12:335-348.
14. 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
15. Rottey S., Slegers G., Van Belle S., Goethals I., Van de Wiele C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006, 47:1813-1818.
16. Toretsky J., Levenson A., Weinberg I.N., Tait J.F., Uren A., Mease R.C. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol 2004, 31:747-752.
17. Tait J.F., Smith C., Levashova Z., Patel B., Blankenberg F.G., Vanderheyden J.L. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med 2006, 47:1546-1553.
18. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 2008, 49:1345-1352.
19. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med 2006, 47:1367-1374.
20. 99mTc(CO)3]+: a new radiopharmaceutical for imaging cell death. Bioconjugate Chemistry 2009, 20:2071-2081.
21. Wyffels L., Gray B.D., Barber C., Woolfenden J.M., Pak K.Y., Liu Z. Synthesis and preliminary evaluation of radiolabeled bis(zinc(II)-dipicolylamine) coordination complexes as cell death imaging agents. Bioorganic & medicinal chemistry 2011, 19:3425-3433.
22. Al-Ejeh F., Darby J.M., Tsopelas C., Smyth D., Manavis J., Brown M.P. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy. PloS one 2009, 4:e4558.
23. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature medicine 2008, 14:1357-1362.
24. Ran S., He J., Huang X., Soares M., Scothorn D., Thorpe P.E. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 2005, 11:1551-1562.
25. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer research 2002, 62:6132-6140.
26. Ran S., Thorpe P.E. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. International journal of radiation oncology, biology, physics 2002, 54:1479-1484.
27. Huang X., Bennett M., Thorpe P.E. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer research 2005, 65:4408-4416.
28. Thorpe P.E. Targeting anionic phospholipids on tumor blood vessels and tumor cells. Thrombosis research 2010, 125(Suppl 2):S134-S137.
29. Jennewein M., Lewis M.A., Zhao D., Tsyganov E., Slavine N., He J., et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. Clin Cancer Res 2008, 14:1377-1385.
30. Yin Y., Kavlie A., Thorpe P.E., Yin Y., Kavlie A., Thorpe P.E. Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice 2009, 5463.
31. Gong J., Him L., Hughes C., Freimark B. Monitoring tumor response to chemotherapy by in vivo real-time imaging of phosphatidylserine targeting antibodies. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. AACR Apr 2-6. Orlando, FL, Abstract 4880 2011, 4880.
32. Perk L.R., Vosjan M.J., Visser G.W., Budde M., Jurek P., Kiefer G.E., et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. European journal of nuclear medicine and molecular imaging 2010, 37:250-259.
33. Wang L.G., Liu X.M., Kreis W., Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer chemotherapy and pharmacology 1999, 44:355-361.
34. Park S.J., Wu C.H., Gordon J.D., Zhong X., Emami A., Safa A.R. Taxol induces caspase-10-dependent apoptosis. The Journal of biological chemistry 2004, 279:51057-51067.
35. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature reviews 2008, 7:1001-1012.
36. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011, 11:123-134.
37. Schoenwaelder S.M., Yuan Y., Josefsson E.C., White M.J., Yao Y., Mason K.D., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
38. 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 2010, 37:289-297.
39. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010, 51:1293-1300.
40. van Dongen G.A., Visser G.W., Lub-de Hooge M.N., de Vries E.G., Perk L.R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007, 12:1379-1389.
41. 89Zr-7E11 immuno-PET. J Nucl Med 2011, 52:1608-1615.